CD4+ T-cell count may not be a useful strategy to monitor antiretroviral therapy response in HTLV-1/HIV co-infected patients. Current HIV Research, : doi: 10.2174/1570162X15666170216114917 (2017).

Publication Latest Publications

Title: CD4+ T-cell count may not be a useful strategy to monitor antiretroviral therapy response in HTLV-1/HIV co-infected patients
Authors: Vandormael A, Rego F, Danaviah S, Alcantara L, Boulware D, de Oliveira T.
Journal: Current HIV Research,:doi: 10.2174/1570162X15666170216114917 (2017)

Journal Impact Factor (I.F.): 1.631
Number of citations (Google Scholar): 2

Abstract

BACKGROUND: HTLV-1/HIV co-infection is known to elevate the CD4+ T-cell counts of treatment-naive persons. We investigated whether HTLV-1/HIV co-infected patients continued to have elevated CD4+ T-cell counts after developing virologic failure on antiretroviral therapy (ART).

METHODS: The data comes from a drug resistance study located in the KwaZulu-Natal province of South Africa. All participants (N=383) presented for repeated CD4+ T-cell count and HIV viral load level testing between January 2006 and March 2014. We used a random-coefficient model to estimate the change in CD4+ T-cell count and HIV viral load level by HTLV-1/HIV co-infection status over time, adjusting for age, sex, and duration of virologic failure.

RESULTS: HTLV-1/HIV co-infected participants (n=8) had higher CD4+ T-cell counts, with a positive difference of 117.2 cells/uL at the ART initiation date (p-value=0.001), 114.7 cells/uL (p-value<0.001) 12 months after this date, and 112.3 cells/uL (p-value=0.005) 24 months after this date, holding all else constant. In contrast, there was no difference in the HIV viral load level by HTLV-1/HIV co-infected status throughout the observation period.

CONCLUSIONS: We show that HTLV-1/HIV co-infected participants continued to have elevated CD4+ T-cell counts after developing virologic failure on ART, despite no difference in their HIV viral load levels when compared with HIV mono-infected participants. Our results indicate that CD4+ T-cell count testing may not be a useful strategy to monitor ART response in the presence of HTLV-1 infection.

Printed and Online Media Coverage

EurekaAlert!

CD4+ T-cell count useful to assess antiretroviral therapy response in HTLV-1/HIV patients?

EurekaAlert! - 2017-03-17

News coverage and clinical management implication of our recent HIV/HTLV co-infection manuscript, Current HIV Research, 2017


IDSE Infectious Diseases

CD4+ Count Not Useful to Assess ART Response in HTLV-1/HIV Coinfection

IDSE Infectious Diseases - 2017-03-21

Patients coinfected with human T-cell lymphotropic virus 1 (HTLV-1) and HIV continue to have elevated CD4+ T-cell counts, even though there is no difference in their HIV viral load levels after antiretroviral therapy when compared with patients who just have HIV (Curr HIV Res 2017).



Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration
Journal: EBioMedicine (2017)

High Rates of Transmission of Drug-resistant HIV in Aruba Resulting in Reduced Susceptibility to the WHO Recommended First-line Regimen in Nearly Half of Newly Diagnosed HIV-infected Patients
Journal: Clinical Infectious Diseases (2017)

Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis
Journal: Clinical Infectious Diseases (2017)
All publications...


KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), K-RITH Tower Building, Nelson R Mandela School of Medicine, UKZN

Contact: Prof. Tulio de Oliveira, Tel: +27 31 260 4898, Email: tuliodna@gmail.com & deoliveira@ukzn.ac.za

Page design updated 2013. Many of the pages were previously hosted at bioafrica.net.